HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?

Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already includes 17 global phase 3 trials. But there's one important missing piece.

By FiercePharma · Jun 1, 2026 · via FiercePharma
ASCO: Sac-TMT's massive phase 3 program has a jarring gap. Does Merck plan to close it?

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
The WeekFierceBiotech ↗
Lilly pens $1.2B deal for Hanmi's GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-s…
Jun 1, 2026
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
The WeekBriefing
Revolution Medicines Preps Daraxonrasib FDA Filing, Starts Early Shipments
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
Jun 1, 2026
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
The WeekBioPharma Dive ↗
2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?
Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline…
Jun 1, 2026